Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7320578 | 0.98 | SIGMAR1 (0.68) | SIGMAR1KDM4EALDH1A1MPOCHRM2 | |
| SCHEMBL8814963 | 0.91 | LTA4H (0.78) | SIGMAR1KDM4EALDH1A1MPOCHRM2 | |
| SCHEMBL11883482 | 0.91 | SIGMAR1 (0.84) | SIGMAR1MPOCHRM2BCHEMAOA | |
| Hydrochloric Acid SCHEMBL6415080 | 0.90 | MPO (0.58) | SIGMAR1KDM4EALDH1A1MPOCHRM2 | |
| SCHEMBL27688886 | 0.89 | KDM4E (0.84) | SIGMAR1KDM4EALDH1A1MPOCHRM2 | |
| SCHEMBL10399489 | 0.89 | KDM4E (0.84) | SIGMAR1KDM4EALDH1A1MPOCHRM2 | |
| SCHEMBL4065566 | 0.89 | SIGMAR1 (0.88) | SIGMAR1MPOCHRM2BCHEMAOA | |
| Bromide SCHEMBL11691228 | 0.87 | SIGMAR1 (0.84) | SIGMAR1MPOCHRM2BCHEMAOA | |
| SCHEMBL9973129 | 0.86 | SIGMAR1 (0.75) | SIGMAR1KDM4EALDH1A1KCNH2 | |
| SCHEMBL14625327 | 0.86 | SIGMAR1 (0.79) | SIGMAR1CHRM2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | SIGMAR1 911/4885KDM4E 1015/4885ALDH1A1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.